$XBI $124.07 +0.5%
Covid Updates
$AZN +0.3% AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial . source
Pipeline Updates
$TPTX -4.0% Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress source
$OCUL +15.4% OCULAR THERAPEUTIX™ ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR DEXTENZA® (DEXAMETHASONE OPHTHALMIC INSERT) 0.4 MG FOR INTRACANALICULAR USE FOR THE TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS source
$SRPT +8.2% Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne. source
$CLSN +5.0% Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews. source
$GOSS +6.5% Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208. source
$PTCT +1.1% Tegsedi® Receives Innovative Drug Category Pricing in Brazil. source
$TCON +8.0% TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001. source
$INO +3.8% INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization. source
$ATNX -10.7% Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer. source
$ALGS -2.2% Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study. source
$PTGX +93,9% Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program. source
$LABP +1.9% Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus. source
$IMRX -18.4% Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. source
$UTHR -1.2% United Therapeutics to Present New Data at CHEST Annual Meeting 2021. source
$FDMT +13.5% 4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting. source
$RGNX +6.1% REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting. source
$ADVM -0.5% Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting. source
Financial & Business Updates
$RLAY +4.0% Relay Therapeutics Announces Proposed Public Offering of Common Stock source
$ATAI +0.2% atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD). source
$PCRX & $FLXN +5.8% & + 58.7% Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management. source
$SUPN & $ADMS +7.8% & +75.1% Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio. source
Posted by FS/JM
Comentarios